JP MORGAN CONFERENCE // JANUARY 12-15 2026 SAN FRANCISCO //..// LURBINECTEDIN / IMFORTE / ROCHE . Let's Hope ROCHE Can Provide The MARKET With The Actual Percentage Of Patients Who, After Being Treated As FIRST-LINE INDUCTION THERAPY For SMALL CELL LUNG CANCER With ATEZOLIZUMAB ... Will Actually Be Able To Access MAINTENANCE THERAPY With IMFORTE .